feed,title,long_url,short_url
r/pennystocks:25+,[:Bolt2: Catalyst] Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission,https://redd.it/txjn6l,
